198 related articles for article (PubMed ID: 23738077)
1. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?
Cucinotto I; Fiorillo L; Gualtieri S; Arbitrio M; Ciliberto D; Staropoli N; Grimaldi A; Luce A; Tassone P; Caraglia M; Tagliaferri P
J Drug Deliv; 2013; 2013():905091. PubMed ID: 23738077
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the clinical benefits of nanoparticle albumin-bound paclitaxel in women with metastatic breast cancer in British Columbia.
Lohmann AE; Speers CH; Chia SK
Curr Oncol; 2013 Apr; 20(2):97-103. PubMed ID: 23559872
[TBL] [Abstract][Full Text] [Related]
4. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
[TBL] [Abstract][Full Text] [Related]
5. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Lipp HP
Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
7. Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?
Palumbo R; Sottotetti F; Bernardo A
Ther Adv Med Oncol; 2016 May; 8(3):209-29. PubMed ID: 27239239
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
10. Albumin-bound paclitaxel: a next-generation taxane.
Gradishar WJ
Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
12. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
13. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
Guarneri V; Dieci MV; Conte P
Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
[TBL] [Abstract][Full Text] [Related]
14. Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.
Yoshida H; Kim YH; Ozasa H; Nagai H; Sakamori Y; Nakaoku T; Yagi Y; Tsuji T; Nomizo T; Mishima M
Mol Clin Oncol; 2016 Jul; 5(1):213-215. PubMed ID: 27330801
[TBL] [Abstract][Full Text] [Related]
15. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Ley J; Wildes TM; Daly K; Oppelt P; Adkins D
Med Oncol; 2017 Feb; 34(2):28. PubMed ID: 28078561
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer.
Takashima S; Kiyoto S; Takahashi M; Hara F; Aogi K; Ohsumi S; Mukai R; Fujita Y
Oncol Lett; 2015 Apr; 9(4):1822-1826. PubMed ID: 25789050
[TBL] [Abstract][Full Text] [Related]
18. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
Chirgwin J; Chua SL
Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
[TBL] [Abstract][Full Text] [Related]
20. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
